351 related articles for article (PubMed ID: 31591605)
21. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
Henao-Restrepo AM; Longini IM; Egger M; Dean NE; Edmunds WJ; Camacho A; Carroll MW; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Hossmann S; Kondé MK; Kone S; Kuisma E; Levine MM; Mandal S; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Watson CH; Kéïta S; Kieny MP; Røttingen JA
Lancet; 2015 Aug; 386(9996):857-66. PubMed ID: 26248676
[TBL] [Abstract][Full Text] [Related]
22. Epitopes of Naturally Acquired and Vaccine-Induced Anti-Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution.
Heidepriem J; Krähling V; Dahlke C; Wolf T; Klein F; Addo MM; Becker S; Loeffler FF
Biotechnol J; 2020 Sep; 15(9):e2000069. PubMed ID: 32463974
[TBL] [Abstract][Full Text] [Related]
23. Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine.
Farooq F; Beck K; Paolino KM; Phillips R; Waters NC; Regules JA; Bergmann-Leitner ES
Sci Rep; 2016 Jun; 6():27944. PubMed ID: 27323685
[TBL] [Abstract][Full Text] [Related]
24. Ebola epidemic in war-torn Democratic Republic of Congo, 2018: Acceptability and patient satisfaction of the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus Vaccine.
Kasereka MC; Sawatzky J; Hawkes MT
Vaccine; 2019 Apr; 37(16):2174-2178. PubMed ID: 30878249
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo.
Hoff NA; Bratcher A; Kelly JD; Musene K; Kompany JP; Kabamba M; Mbala-Kingebeni P; Dighero-Kemp B; Kocher G; Elliott E; Reilly C; Halbrook M; Ilunga Kebela B; Gadoth A; Ngoie Mwamba G; Tambu M; McIlwain DR; Mukadi P; Hensley LE; Ahuka-Mundeke S; Rutherford GW; Muyembe-Tamfum JJ; Rimoin AW
Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35110410
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
[TBL] [Abstract][Full Text] [Related]
27. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.
Huttner A; Agnandji ST; Combescure C; Fernandes JF; Bache EB; Kabwende L; Ndungu FM; Brosnahan J; Monath TP; Lemaître B; Grillet S; Botto M; Engler O; Portmann J; Siegrist D; Bejon P; Silvera P; Kremsner P; Siegrist CA; ; ;
Lancet Infect Dis; 2018 Jul; 18(7):738-748. PubMed ID: 29627147
[TBL] [Abstract][Full Text] [Related]
28. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
[TBL] [Abstract][Full Text] [Related]
29. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
[TBL] [Abstract][Full Text] [Related]
30. Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.
Medaglini D; Siegrist CA
Curr Opin Virol; 2017 Apr; 23():88-94. PubMed ID: 28460340
[TBL] [Abstract][Full Text] [Related]
31. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
32. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya.
Mutua G; Anzala O; Luhn K; Robinson C; Bockstal V; Anumendem D; Douoguih M
J Infect Dis; 2019 Jun; 220(1):57-67. PubMed ID: 30796816
[TBL] [Abstract][Full Text] [Related]
33. Effect of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo.
Rupani N; Ngole ME; Lee JA; Aluisio AR; Gainey M; Perera SM; Ntamwinja LK; Matafali RM; Muhayangabo RF; Makoyi FN; Laghari R; Levine AC; Kearney AS
Emerg Infect Dis; 2022 Jun; 28(6):1180-1188. PubMed ID: 35608607
[TBL] [Abstract][Full Text] [Related]
34. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.
Marzi A; Ebihara H; Callison J; Groseth A; Williams KJ; Geisbert TW; Feldmann H
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1066-74. PubMed ID: 21987743
[TBL] [Abstract][Full Text] [Related]
35. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A
mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339
[TBL] [Abstract][Full Text] [Related]
36. Ebola vaccine trials: progress in vaccine safety and immunogenicity.
Matz KM; Marzi A; Feldmann H
Expert Rev Vaccines; 2019 Dec; 18(12):1229-1242. PubMed ID: 31779496
[No Abstract] [Full Text] [Related]
37. Open-label phase I clinical trial of Ad5-EBOV in Africans in China.
Wu L; Zhang Z; Gao H; Li Y; Hou L; Yao H; Wu S; Liu J; Wang L; Zhai Y; Ou H; Lin M; Wu X; Liu J; Lang G; Xin Q; Wu G; Luo L; Liu P; Shentu J; Wu N; Sheng J; Qiu Y; Chen W; Li L
Hum Vaccin Immunother; 2017 Sep; 13(9):2078-2085. PubMed ID: 28708962
[TBL] [Abstract][Full Text] [Related]
38. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
[TBL] [Abstract][Full Text] [Related]
39. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
Front Immunol; 2021; 12():706757. PubMed ID: 34335620
[TBL] [Abstract][Full Text] [Related]
40. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
